Study pinpoints how long it takes to regain weight after stopping weight loss jabs - and it's quicker than you think
More than a million people in the UK are now injecting themselves weekly with drugs such as Mounjaro and Wegovy—bought online or through private clinics—lured by promises of rapid results.
Known collectively as GLP-1s, the weekly injections can see users lose up to a fifth of their body weight in as little as a year, upending the obesity treatment playbook.
But now experts in metabolic medicine, from Peking University People's Hospital, Beijing, have warned that the results are likely to be short-lived if patients do not maintain a healthy lifestyle after coming off the jabs.
Even those taking newer, more powerful jabs like Mounjaro were found to regain the weight once treatment was stopped.
The researchers, led by Professors Xiaoling Cai and Lingong Ji, found that even those on trizeparide—the so-called 'King Kong' of weight loss jabs, regained almost half the weight they had previously lost after coming off the drug and switching to a placebo.
Whilst the study, published in the journal BMC Medicine, didn't explain exactly why people pile the weight back on so fast, the researchers speculated it could be due to a phenomenon known as 'weight cycling.'
This refers to the process of regaining weight after stopping treatment, and can be due to a number of factors.
One potential reason for rapid weight gain after coming off the jabs could be due to hormonal changes in the gut.
According to the researchers, previous studies with very low energy diets show that weight loss induces adverse hormonal changes in the gut that potentially affect weight regain after treatment.
'This adverse hormonal change in the gut causes an increase in hunger levels and urge to eat, which promotes weight regain,' Prof Cai explained.
Other experts, such as Professor Susan Jebb, who was not involved in the study, have speculated the post-treatment weight gain could simply be because diets are hard.
No self restraint is required when taking the drugs, so people don't have effective 'behavioural strategies in place' when they stop taking them.
The injections trigger weight loss by mimicking the actions of a hormone released in the gut after eating called GLP-1.
As well as signalling to the pancreas to make more insulin, this hormone feeds back to the brain, stopping users from overeating.
The findings could raise issues for both the Government, which plans to roll out a new £85million weight loss jab trial involving tens of thousands of people offered the drug, and manufacturers such as Eli Lily who announced last week they are increasing the price of their products in the UK.
Despite many being eager to take the drugs, the revolutionary jabs are not without side effects, and as such currently only patients with a body mass index (BMI) over 30 and at least one weight-related health problem can qualify for treatment.
UK law forbids the sale of drugs such as Wegovy without a prescription from a medical professional.
Common side-effects include nausea, constipation and diarrhoea after taking the medication and many users have spoken out about struggling to keep the weight off after stopping the medication.
Some doctors have also warned they are seeing patients with serious, life-threatening complications including seizures, bowel obstructions and inflammation of the pancreas, known as pancreatitis.
Healthcare watchdog NICE currently advises that users should not be on the injections for more than two years.
Tam Fry, chairman of the National Obesity Forum, added: 'It shouldn't surprise anyone if people regain weight having used GLP-1 drugs without seriously attempting to improve their lifestyle.
'Using GLP1-s is not the quick fix which many users believe it to be.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
an hour ago
- Daily Mirror
Parents told stop giving children gummies 'immediately' - full list of symptoms
The Government has issued an urgent warning to parents - dispose of the gummies as soon as possible Parents who have bought nutrition supplement gummies for their children have been told to stop using them immediately. Nutrition Ignition Kids Magnesium Glycinate Gummies should be 'safely disposed of', according to the Medicines and Healthcare products Regulatory Agency (MHRA). A spokesman said: "It is recommended that advice be sought from a healthcare professional if a child has any side effects that are of concern." The MHRA is advising parents and caregivers to stop all use of Nutrition Ignition Kids Magnesium Glycinate Gummies, due to the presence of undeclared melatonin, a prescription-only medicine. Testing of two batches by the MHRA identified melatonin within the product. The gummies tested were found to contain between 1.5 and 1.7mg of melatonin in each individual gummy. Depending on the age of the child, the product packaging advised a dose of 1 or 2 gummies per day. Melatonin is not listed anywhere on the product's packaging. Taking too much melatonin can cause drowsiness, headache, dizziness, and nausea. Lasting harm is not expected when ingesting melatonin at high levels, and the body typically clears this within 12 hours. The product has only been sold online as a food supplement, however, given the presence of a medicine, the MHRA took action to remove the product from sale, working with online retailers to withdraw all listings. Anyone with this product at home is advised to store it securely in a tamper-proof container out of reach of children until they can take it to any pharmacy for disposal. Melatonin is authorised for use in the UK as a prescription medicine for specific sleep disorders in both adults and children over the age of 6 years, where other sleep management approaches have been insufficient. If prescribed, the recommended starting dose of melatonin is 1mg for children. The dose in children can be increased to a maximum of 5mg per day before bed. The suggested use of Nutrition Ignition Kids Magnesium Glycinate Gummies is for children aged 4 years-old and above to support 'calm, focus, and digestion'. Dr Alison Cave, MHRA Chief Safety Officer, said: 'We advise any parent or caregiver to stop use of this product and safely dispose of it. Side effects such as headache, hyperactivity, a feeling of dizziness and abdominal pain have been reported in children when melatonin is prescribed and used for its licensed indications. No serious side effects were observed in studies in children. 'Anyone who suspects that their child, or a child in their care, is having a side effect from this product is advised to stop taking it and speak to a healthcare professional and report it directly to the MHRA Yellow Card scheme.
Daily Mail
an hour ago
- Daily Mail
Ozempic for DOGS: Scientists are testing an implant for fat pooches that mimics weight-loss drugs taken by humans
Weight-loss drugs like Ozempic have already helped hundreds of thousands of humans to slim down. Now, scientists want to develop drugs that could help dogs ditch their puppy fat. One biotech firm has now announced trials for an implant that mimics the effects of Ozempic's active ingredient in dogs. Okava, one of the companies involved in the trial, says their doggy-Ozempic could be on the market as soon as 2028. The drugs Ozempic and Wegovy contain a chemical called semaglutide, which is a class of medication known as a 'GLP-1 receptor agonist'. This means that it mimics the GLP-1 hormone in our bodies and suppresses the appetite by controlling blood sugar levels, helping people lose weight. While these exact chemicals don't work in dogs, biotech firms are looking to find alternatives which reproduce the same effects, known as 'GLP-1 mimics'. Scientists say these drugs could help prevent pooches' begging behaviour, which owners find so hard to resist. Just like in humans, obesity in pets can lead to a range of related health conditions and exacerbate underlying illnesses. For example, overweight dogs are at a higher risk of arthritis, heart disease, breathing issues, and cancer. However, obesity among dogs is at what some vets consider 'crisis' levels, with over half of all dogs being considered overweight according to research by the trade body UK Pet Food. In order to tackle this growing problem, some biotech firms are now looking for potential chemical interventions. Okava has partnered with the biotech firm Vivani Medical to produce a long-lasting implant that could help both dogs and cats lose weight. Roughly the size of a standard tracking chip, the implant would be delivered once every six months and sit below the skin to release a steady supply of weight-loss drugs. Instead of using semaglutide, this implant would use an alternative GLP-1 mimic called OKV-119, which has been found to be safe in cats. The company is currently planning trials in dogs and plans to release the implant commercially sometime in either 2028 or 2029. According to the company, this should reduce the food-obsessive behaviours that lead to humans overfeeding their pets. For some vets and owners, this treatment could be an extremely valuable option to help tackle persistent obesity in dogs. Professor Alex German, a dog obesity expert from the University of Liverpool, told Daily Mail: 'Having an alternative approach, such as drugs, could be useful for clinicians on the ground to have an extra option.' Although feeding habits and training play a big role in putting on excess weight, Dr German says that obesity is a far more complex condition than most people realise. Dr German says that his clinic constantly deals with pet owners who are 'desperate to help their pets, but they face a major challenge.' The current approach to treating pet obesity involves a 'therapeutic diet' which restricts calorie intake while keeping nutrient levels appropriate. However, Dr German says that this is a 'massive years-long, often life-long challenge' that doesn't always work for every dog. 'There's a massive genetic component that drives the animal to be hungry all the time,' says Dr German. If GLP-1 mimics are proven to be effective, they could be a useful alternative or supplement to therapeutic diets. However, Dr German warns that these treatments could cause behavioural side-effects that some users might not like. A weight-loss drug for dogs named Slentrol was launched in 2007, which worked by suppressing the appetite. However, the drug failed to perform well on the market and was eventually discontinued, partially because owners didn't like how their dogs began to act. Dr German says: 'Normally, the dog would be waiting at the door to greet them; delighted, happy, wagging their tail. 'But, because they weren't hungry, some of that behaviour and interaction with the owner changed - the suppression of the appetite was something that was seen as a negative by the owners.' If GLP-1 mimics are going to be successful this time around, Dr German says owners will likely need counselling and support to ensure they understand any potential behaviour changes. However, some vets are not convinced that GLP-1 mimics are necessary for treating obesity in pets, even if the drugs do work. Dogs often become obese due to what vets call 'pester power', meaning they are better at begging for food than their owners are at saying no. Combined with insufficient exercise, old age, or neutering, pets can quickly gain excess weight. That means if your pooch is starting to pile on the pounds, a stricter diet and more exercise are the best place to start. Dr Helen Zomer, of the University of Florida, told Daily Mail: 'We don't have definitive answers whether it would be a good solution or potential consequences. 'Controlled caloric intake through balanced diets and physical activity remains the best solution right now.' Overweight people are more than twice as likely to have overweight dogs, a 2019 study found. The team of Danish study authors said this is at least partly because they are guilty of feeding their pets fattening treats. Writing in their study the authors claim this lends credence to the saying 'like owner, like dog'. 'The prevalence of heavy or obese dogs is more than twice as large among overweight or obese owners (35 per cent) than among owners who are slim or of a normal weight (14 per cent),' the researchers from the University of Copenhagen said. Of the 268 dogs studied, 20 per cent were found to be overweight. Average–weight owners tend to use treats for training purposes while overweight owners prefer to provide treats far more often. The study's main author, Charlotte Bjornvad, said: 'For example, when a person is relaxing on the couch and shares the last bites of a sandwich or a cookie with their dog.'
The Independent
2 hours ago
- The Independent
Ozempic sales surge ‘up to 600%' after Mounjaro price rises
Sales of weight loss drug Ozempic are reportedly up by 500 to 600 per cent in Britain following the announcement of price rises of its popular competitor Mounjaro. Eli Lilly, the manufacturer of Mounjaro, said prices of the drug will almost triple from 1 September to bring it in line with other countries. Ozempic, also known under the brand name Wegovy, is manufactured by Denmark's Novo Nordisk, and will now be around half the price of Mounjaro. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. Mr Trump explained in May that his plan to impose price controls on prescription medications was inspired by hearing from a friend about the low cost of weight-loss medication in the UK compared to what that person paid for the same medication in the US. He told reporters of taking a call from a 'friend' in London, who he described as a 'highly neurotic, brilliant businessman' and 'seriously overweight', about the cost of what Mr Trump described as 'the fat shot drug'. Mr Trump said, according to his friend: 'I'm in London, and I just paid for this damn fat drug I take. I said, it's not working. They said, he said, I just paid $88 and in New York I paid $1,300. What the hell is going on? he said. So I checked, and it's the same box made in the same plant by the same company. It's the identical pill that I buy in New York, and here I'm paying $88 in London, in New York, I'm paying $1,300.' The price hikes by Eli Lilly mean a month's supply of the highest doses of Mounjaro - the ' King Kong ' of weight loss medicine - will rise from £122 to £330, which is an increase of 170 per cent. The shift to Ozempic is "continuing to run at about 500 to 600 per cent at the moment, and we are not surprised to see that", said Toby Nicol, founder and chief executive of Chequp, a provider of the weight loss treatment. "People living with obesity have been waiting for weight loss drugs for decades. They are literally the magic bullet for many people and they suddenly find that the drug they're on has doubled in price," he told The Independen t, adding: "But hey, there's one which is almost as good. "We understand why they've done it, but the impact on patients is very dramatic. People encouraged to start a weight-loss journey, have now been told the prices are going up. It's a kick in the teeth for them, it really is." He warned patients should only switch treatments under the supervision of a trusted pharmacist to manage any potential health risks. Eli Lilly said when it launched Mounjaro in the UK, it agreed to a list price ' significantly below ' that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said last week. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Prices paid by the NHS for the drug will not rise after the health service negotiated a substantial discount for patients taking the drug on prescription.
